公开(公告)号：US20220206015A1

公开(公告)日：2022-06-30

申请号：US17693789

申请日：2022-03-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Dirk BLOCK ,  Hanspeter BRUNNER ,  Thomas DIETERLE ,  Ursula-Henrike WIENHUES-THELEN ,  Christian ZAUGG ,  Andre ZIEGLER

IPC: G01N33/68 ,  A61K31/40 ,  G01N33/62

Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.